Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

VYNE Therapeutics Inc. VYNE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.75
+823.1%

VYNE Therapeutics Inc. (VYNE) is a Biotechnology company in the Healthcare sector, currently trading at $0.62. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is VYNE = $6 (+823.1% upside).

Valuation: VYNE trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25).

Financials: revenue is $570,000, +6.9%/yr average growth. Net income is $26M (loss), growing at +3.2%/yr. Net profit margin is -4646.1% (negative). Gross margin is 96% (-4 pp trend).

Balance sheet: total debt is $0 against $28M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 12.53 (strong liquidity). Debt-to-assets is 0%. Total assets: $30M.

Analyst outlook: 1 / 2 analysts rate VYNE as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 55/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 41/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$5.75
▲ 823.1% Upside
Average Price Target
The 12-month price target for VYNE Therapeutics Inc. is $5.75.

VYNE SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 55/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VYNE

✓
VALUE Pass
100/100
VYNE trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25). Forward PEG -0.12 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $6, implying +863.2% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
55/100
VYNE: +6.9%/yr revenue is, +3.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet VYNE: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 12.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
VYNE: Gross margin is 96% (-4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 1 / 2 analysts rate VYNE as buy (50%). Analyst consensus target is $6 (+863.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VYNE: Net profit margin is -4646.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.281-1.993
Volume84.01K
Avg Volume (30D)299.52K
Market Cap$10.38M
Beta (1Y)1.95
Share Statistics
EPS (TTM)-0.62
Shares Outstanding$42.77M
IPO Date2018-01-25
Employees13
CEODavid T. Domzalski
Financial Highlights & Ratios
Revenue (TTM)$570K
Gross Profit$547K
EBITDA$-26.73M
Net Income$-26.48M
Operating Income$-29.75M
Total Cash$29.01M
Net Debt$-24.03M
Total Assets$30.16M
Price / Earnings (P/E)-1
Price / Sales (P/S)18.21
Analyst Forecast
1Y Price Target$5.75
Target High$5.75
Target Low$5.75
Upside+823.1%
Rating ConsensusBuy
Analysts Covering2
Buy 50% Hold 50% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92941V3087

Price Chart

Track all markets on TradingView
VYNE
VYNE Therapeutics Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.28 52WK RANGE 1.99

People Also View

CDTX
CDTX
Cidara Therapeutics, Inc.
$221.38
+0.00%
 VCYT
VCYT
Veracyte, Inc.
$34.30
+5.73%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
 KRON
KRON
Kronos Bio, Inc.
$0.88
+1.49%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message